Literature DB >> 3197913

The use of low molecular weight heparins for postsurgical deep vein thrombosis prevention in orthopaedic patients.

E Chiapuzzo1, G B Orengo, G Ottria, A Chiapuzzo, E Palazzini, M Fusillo.   

Abstract

The prophylactic antithrombotic efficacy of a low molecular weight heparin was compared with a traditional unfractionated calcium heparin after orthopaedic surgery in 140 patients. Deep vein thromboses were detected in legs either by Doppler sonography or [125I]fibrinogen uptake tests in five (7.1%) and seven (10%) patients, respectively. The capacity of both drugs to prevent deep vein thrombosis was demonstrated. Compared with the control group, those who used low molecular weight heparin showed a significant increase of activated factor X inhibition and smaller increases in activated partial thromboplastin times. Tolerability of both drugs was good, with a low incidence of local side-effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197913     DOI: 10.1177/030006058801600505

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  7 in total

1.  Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery.

Authors:  R Ferriols-Lisart; F Ferriols-Lisart; V Jiménez-Torres
Journal:  Pharm World Sci       Date:  2002-06

2.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

Review 3.  Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.

Authors:  J E Frampton; D Faulds
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 4.  Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 6.  Update on the clinical use of the low-molecular-weight heparin, parnaparin.

Authors:  Giuseppe Camporese; Enrico Bernardi; Franco Noventa
Journal:  Vasc Health Risk Manag       Date:  2009-10-12

Review 7.  Clinical use of parnaparin in major and minor orthopedic surgery: a review.

Authors:  Stefano Bugamelli; Elena Zangheri; Milena Montebugnoli; Lucia Guerra
Journal:  Vasc Health Risk Manag       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.